Evidence map›Paper›PMID 35617770›Full record

Trial reportMaturitas2022

Cardiometabolic measures and cognition in early menopause - Analysis of baseline data from a randomized controlled trial.

Lubna Pal, Kelly Morgan, Nanette F Santoro, JoAnn E Manson, Hugh S Taylor, Virginia M Miller, Eliot A Brinton, Rogerio Lobo, Genevieve Neal-Perry, Marcelle I Cedars and 3 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Maturitas, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lubna PalDepartment of Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, CT, United States. Electronic address: lubna.pal@yale.edu.
Kelly MorganSSM Health Dean Medical Group, Madison, WI, United States.
Nanette F SantoroDepartment of Obstetrics, Gynecology, University of Colorado, Denver, United States.
JoAnn E MansonDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, United States.
Hugh S TaylorDepartment of Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, CT, United States.
Virginia M MillerDepartment of Surgery, Mayo Clinic, United States; Department of Physiology and Biomedical Engineering, Mayo Clinic, United States.
Eliot A BrintonUtah Lipid Center, United States.
Rogerio LoboDepartment of Obstetrics and Gynecology, Columbia University, United States.
Genevieve Neal-PerryDepartment of Obstetrics and Gynecology, The University of North Carolina at Chapel Hill, United States.
Marcelle I CedarsDepartment of Obstetrics, Gynecology and Reproductive Sciences, UCSF, United States.
S Mitchell HarmanKronos Longevity Research Institute and the Phoenix Veterans Administration Health Care System, Phoenix, AZ, United States.
Taryn T JamesDivision of Geriatrics, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison Geriatric Research Education and Clinical Center (GRECC), United States.
Carey E GleasonDivision of Geriatrics, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison Geriatric Research Education and Clinical Center (GRECC), United States.

Funding

University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sanjay Asthana · 2019 to 2026
$34.5M
INSTITUTIONAL CTSA (UW-MADISON): CLINICAL TRIALSUL1RR025011 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2007 to 2011
$29.5M
African Americans Fighting Alzheimer’s in Midlife (AA-FAIM)R01AG054059 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI CAREY E GLEASON · 2016 to 2026
$15.3M
Prevention of Alzheimer's disease in women: risks and benefits of hormone therapyRF1AG057547 · NIA · MAYO CLINIC ROCHESTER · PI GLEASON, CAREY E, KANTARCI, KEJAL · 2017 to 2020
$11.1M
Indigenous Cultural Understandings of Alzheimer's Disease and Related Dementias - Research and Engagement (I-CARE)R01AG062307 · NIA · UNIVERSITY OF MINNESOTA · PI JACKLIN, KRISTEN · 2021 to 2025
$7.5M
KEEPS Cognitive and Affective StudyR01AG029624 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI ASTHANA, SANJAY · 2007 to 2013
$3.4M
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for ADR01AG031790 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI CARLSSON, CYNTHIA M · 2009 to 2013
$1.6M
NCATS NIH HHS UL1 TR002373NCRR NIH HHS UL1 RR025011NIA NIH HHS P30 AG062715NIA NIH HHS R01 AG029624NIA NIH HHS R01 AG031790NIA NIH HHS R01 AG054059NIA NIH HHS R01 AG062307NIA NIH HHS RF1 AG057547
6 · The paper itself

Abstract

objectiveThe relationships between cardiometabolic indices and cognition were examined in recently menopausal women.

methodsCross-sectional analysis of baseline data from the KEEPS (Kronos Early Estrogen Prevention Study)-Cognitive ancillary study (n = 621). Cognitive performance was assessed by the Modified Mini Mental Status (3MS) score (primary outcome). Physical cardiometabolic indices included body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), and blood pressure (BP). Biochemical cardiometabolic indices included serum levels of high sensitivity C-reactive protein (hs-CRP), total cholesterol (TC), low-density lipoprotein (LDL-C), high-density lipoprotein (HDL-C), non-HDL (non-HDL-C), triglycerides (TG), fasting serum glucose (FSG), and insulin resistance (HOMA-IR). Socio-demographic variables included age, race/ethnicity, education, and lifestyle (physical activity, smoking). Central adiposity was defined as WC > 88 cm (>35 in) and WHR > 0.8. Separate stepwise multivariable analyses (GLM, ordinal logistic regression and logistic regression) assessed relationships between 3MS scores (as continuous, in tertiles and dichotomized at 90 respectively) with the measures of central adiposity (predictor variables); socio-demographic variables (age, time since menopause, race, educational status and lifestyle) and cardiometabolic variables (BP, lipids, FSG, HOMA-IR and hs-CRP) were examined as covariates. The final multivariable models included time since menopause, race, ethnicity, educational status, strenuous exercise, BMI ≥30 kg/m

resultsOn adjusted analyses, indices of central adiposity were independent predictors of significantly lower 3MS scores (p < 0.05). Consistency in this relationship was observed across the three different multivariable regression analytic approaches (GLM, ordinal and logistic regression).

conclusionsAmong recently menopausal women, WC > 88 cm and WHR > 0.8 were associated with significantly lower cognitive function, as reflected by lower 3MS scores. The mechanisms that might explain the observed negative implications of central adiposity for cognitive function warrant further study.

Indexed as

Cardiovascular DiseasesC-Reactive ProteinBody Mass IndexCognitionCross-Sectional StudiesFemaleHumansMenopauseObesityObesity, AbdominalRisk FactorsWaist CircumferenceC-Reactive ProteinCentral adiposityCognitionMenopauseObeseWaist circumferenceWaist:hip ratio

Identifiers

PMID35617770
PMCPMC10089771

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.